BIO-key International, Inc. (NASDAQ:BKYI) Short Interest Down 26.6% in June

Share on StockTwits

BIO-key International, Inc. (NASDAQ:BKYI) saw a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 27,800 shares, a drop of 26.6% from the May 30th total of 37,900 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average trading volume of 11,400 shares, the short-interest ratio is currently 2.4 days.

Separately, Maxim Group set a $8.00 price objective on TrovaGene and gave the company a “buy” rating in a research note on Tuesday, April 2nd.

Shares of NASDAQ BKYI remained flat at $$1.24 during trading on Thursday. The company’s stock had a trading volume of 5,900 shares, compared to its average volume of 20,155. The company’s 50-day moving average is $1.16. BIO-key International has a twelve month low of $0.75 and a twelve month high of $2.70. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.15 and a quick ratio of 1.56.

BIO-key International (NASDAQ:BKYI) last released its quarterly earnings data on Wednesday, May 15th. The technology company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.09). The company had revenue of $0.55 million for the quarter. BIO-key International had a negative net margin of 172.60% and a negative return on equity of 60.41%.

BIO-key International Company Profile

BIO-key International, Inc develops and markets fingerprint biometric identification and identity verification technologies, authentication-transaction security technologies, and related identity management and credentialing biometric hardware and software solutions. Its solutions enable application developers, value added resellers, and channel partners to integrate fingerprint biometrics into their applications.

Featured Story: Why Net Income is Important to Investors

Receive News & Ratings for BIO-key International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-key International and related companies with's FREE daily email newsletter.